Cover Image
市場調查報告書

胃癌:流行病學·基於患者之市場預測,治療流程,上市藥·開發平台藥物分析

Gastric cancer: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365190
出版日期 內容資訊 英文 249 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
胃癌:流行病學·基於患者之市場預測,治療流程,上市藥·開發平台藥物分析 Gastric cancer: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年07月01日 內容資訊: 英文 249 Pages
簡介

本報告提供胃癌治療藥市場相關調查分析,市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:胃癌

  • 摘要整理
  • 市場概要·趨勢
  • 市場定義·手法
  • Avelumab
  • BBI608 (napabucasin)
  • Cyramza (ramucirumab)
  • GS-5745
  • Herceptin (trastuzumab)
  • Keytruda (pembrolizumab)
  • Lynparza (olaparib)
  • Nimotuzumab
  • Opdivo (nivolumab)
  • Perjeta (pertuzumab)
  • 1次調查手法

治療:胃癌

  • 摘要整理
  • 1次調查手法
  • 疾病定義·診斷
  • 患者區分
  • 各國治療樹
  • 目前治療選擇
  • 處方趨勢

流行病學:美國·日本·EU5個國家的胃癌

  • 摘要整理
  • 資訊來源·手法
  • 預測
  • 流行病學者的考察
  • 優點·缺點

上市藥:胃癌

  • 摘要整理
  • 產品概要
  • 產品簡介:Cyramza
  • 產品簡介:Herceptin

開發平台:胃癌

  • 摘要整理
  • 臨床實驗平台概要
  • 產品簡介 (後期) :BBI608
  • 產品簡介 (後期) :GS-5745
  • 產品簡介 (後期) :Keytruda
  • 產品簡介 (後期) :Lynparza
  • 產品簡介 (後期) :Opdivo
  • 產品簡介 (後期) :Perjeta
  • 產品簡介 (後期) :avelumab
  • 產品簡介 (後期) :nimotuzumab

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5561

Pipeline therapies will look to fulfil many areas of high unmet need left by the lack of targeted therapies approved for the treatment of gastric cancer.

This report addresses the following questions:

  • What impact will the PD-1/PD-L1 inhibitor class of drugs have on the gastric cancer market?
  • How will pipeline immunotherapies be positioned in the gastric cancer treatment space?
  • Which targeted therapies are expected to experience the greatest growth over the forecast period?
  • How will Eli Lilly look to maintain Cyramza's first-to-market advantage?
  • What are the key drivers of the rapidly expanding gastric cancer market?

TABLE OF CONTENTS

FORECAST: GASTRIC CANCER

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Avelumab
  • 5. BBI608 (napabucasin)
  • 6. Cyramza (ramucirumab)
  • 7. GS-5745
  • 8. Herceptin (trastuzumab)
  • 9. Keytruda (pembrolizumab)
  • 10. Lynparza (olaparib)
  • 11. Nimotuzumab
  • 12. Opdivo (nivolumab)
  • 13. Perjeta (pertuzumab)
  • 14. Primary Research Methodology

TREATMENT: GASTRIC CANCER

  • 15. Executive Summary
  • 16. Primary Research Methodology
  • 17. Disease Definition and Diagnosis
  • 18. Patient Segmentation
  • 19. Country Treatment Trees
  • 20. Current Treatment Options
  • 21. Prescribing Trends

EPIDEMIOLOGY: GASTRIC CANCER IN THE US, JAPAN, AND 5EU

  • 22. Executive Summary
  • 23. Sources and Methodology
  • 24. Forecast
  • 25. Epidemiologist Insight
  • 26. Strengths and Limitations

MARKETED DRUGS: GASTRIC CANCER

  • 27. Executive Summary
  • 28. Product Overview
  • 29. Product profile: Cyramza
  • 30. Product profile: Herceptin

PIPELINE: GASTRIC CANCER

  • 31. Executive Summary
  • 32. Clinical Pipeline Overview
  • 33. Product profile (late stage): BBI608
  • 34. Product profile (late stage): GS-5745
  • 35. Product profile (late stage): Keytruda
  • 36. Product profile (late stage): Lynparza
  • 37. Product profile (late stage): Opdivo
  • 38. Product profile (late stage): Perjeta
  • 39. Product profile (late stage): avelumab
  • 40. Product profile (late stage): nimotuzumab
Back to Top